Director/PDMR Shareholding

18 Dec 2006 09:37

VASTox plc18 December 2006 VASTox plc ("VASTox" or "the Company") Directors' Shareholdings Oxford, UK, 18 December 2006 - VASTox plc (AIM: VOX) was notified today of thepurchase of 36,000 ordinary shares of 10p each ("Ordinary Shares") by ColinWall, a non-executive director of the Company, representing 0.09 per cent of theissued share capital of the Company. These are the only Ordinary Shares held byColin Wall. Colin Wall joined the VASTox Board of Directors in September 2006 as anon-executive director and Chairman of the Remuneration Committee. VASTox also announces that Darren Millington, VASTox's Chief Financial Officer,has been awarded an option over 250,000 ordinary 1p shares. The share options have an exercise price of 136 pence, being the closing shareprice prior to the award, and vest in equal instalments over a three-year periodsubject to the scheme rules. Following this award Mr Millington holds options over 400,000 ordinary shares,representing 1.07 per cent of the issued share capital of the Company. - ends - For more information, please contact: VASTox Steven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443910Darren Millington, Chief Financial Officer Citigate Dewe Rogerson Tel: +44 (0)207 638 9571Mark Swallow, PhD / David Dible / Valerie Auffray About VASTox plc VASTox is a biotechnology technology company that discovers and developsproprietary novel drugs and provides services to the pharmaceutical industry.The company's most advanced drug development programme is focused on developinga new treatment for Duchenne muscular dystrophy based on the up-regulation ofutrophin. A second drug development programme for spinal muscular atrophy isalso progressing rapidly. VASTox has additional programmes focused onosteoarthritis, cancer, tuberculosis and stem cell therapies, which are expectedto be out-licensed prior to entering the clinic. The company's chemical genomics technology platform, which uses zebrafish andfruitflies, has the potential to dramatically reduce the time and cost of drugdiscovery and development. This is because using whole organisms allows VASToxto carry out high volume, high content screening that delivers data which ishighly predictive of the efficacy and toxicity of potential drug compounds inhumans. VASTox is growing revenues based on marketing its unique technologyplatform and its chemistry expertise. The company listed on the AIM market ofthe London Stock Exchange in October 2004. Further information about the company is available at www.vastox.com. This information is provided by RNS The company news service from the London Stock Exchange